scholarly journals Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders

2022 ◽  
Author(s):  
Johannes M. Sperlich ◽  
Bodo Grimbacher ◽  
Veronika Soetedjo ◽  
Sarita Workman ◽  
Siobhan O. Burns ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Respiratory Tract ◽  
Common Variable Immunodeficiency ◽  
Respiratory Tract Infections ◽  
Forced Expiratory Volume ◽  
Serum Immunoglobulin ◽  
Tract Infections ◽  
Common Variable

AbstractBronchiectasis is a frequent complication of common variable immunodeficiency disorders (CVID). In a cohort of patients with CVID, we sought to identify predictors of bronchiectasis. Secondly, we sought to describe the impact of bronchiectasis on lung function, infection risk, and quality of life. We conducted an observational cohort study of 110 patients with CVID and an available pulmonary computed tomography scan. The prevalence of bronchiectasis was 53%, with most of these patients (54%) having mild disease. Patients with bronchiectasis had lower median serum immunoglobulin (Ig) concentrations, especially long-term IgM (0 vs 0.25 g/l; p < 0.01) and pre-treatment IgG (1.3 vs 3.7 g/l; p < 0.01). CVID patients with bronchiectasis had worse forced expiratory volume in one second (2.10 vs 2.99 l; p < 0.01) and an annual decline in forced expiratory volume in one second of 25 ml/year (vs 8 ml/year in patients without bronchiectasis; p = 0.01). Patients with bronchiectasis also reported more annual respiratory tract infections (1.77 vs 1.25 infections/year, p = 0.04) and a poorer quality of life (26 vs 14 points in the St George’s Respiratory Questionnaire; p = 0.02). Low serum immunoglobulin M concentration identifies patients at risk for bronchiectasis in CVID and may play a role in pathogenesis. Bronchiectasis is relevant because it is associated with frequent respiratory tract infections, poorer lung function, a greater rate of lung function decline, and a lower quality of life.

Assessing the Quality of Life of Children’s with Acute Respiratory Tract Infections

2021 ◽  
Vol 14 (1) ◽  
pp. 32-40
Author(s):  
Jothieswari Dhamotharan ◽  
Durga Prasad Dinesh Kumar ◽  
Lakshmi Raj Sulochana Rajasekaran ◽  
Vinnayak Mondal ◽  
Rachana Panner Selvan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Acute Respiratory Tract Infections ◽  
Tract Infections

Nasal disease and quality of life in athletes

2018 ◽  
Vol 132 (9) ◽  
pp. 812-815
Author(s):  
A C Walker ◽  
P Surda ◽  
M Rossiter ◽  
S A Little
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Nasal Symptoms ◽  
Nasal Disease ◽  
Upper Respiratory ◽  
Tract Infections

AbstractObjectivesNasal disease imposes a significant disease burden upon the individual in the general population, but is relatively under studied in athletes. This study sought to define the frequency of nasal symptoms in the active population, and to quantify the impact of these symptoms on quality of life and on the frequency of upper respiratory tract infections.ResultsA total of 296 participants completed the study (246 athletes and 50 sedentary controls). Nasal symptoms were significantly more frequent in the active group than in the sedentary controls (70 per cent vs 52 per cent). Upper respiratory tract infections were significantly more common in athletes with regular nasal symptoms than in athletes without nasal symptoms. Quality-of-life scores, as measured by the 22-item Sino-Nasal Outcome Test, were significantly worse in athletes with regular nasal symptoms.ConclusionThis study suggests that regular exercise is associated with a significant increase in the prevalence of troubling nasal symptoms, and nasal symptoms in athletes are associated with increased susceptibility to upper respiratory tract infections. Quality of life was negatively affected, confirming the importance of nasal health to athlete welfare.

Quality of life in patients with smell loss due to upper respiratory tract infections

2011 ◽  
Vol 32 (6) ◽  
pp. 504-510 ◽  
Author(s):  
Adolfo Toledano ◽  
Gil Rodríguez ◽  
Ana María Martín ◽  
Tomás Onrubia ◽  
Néstor Galindo
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Smell Loss

scholarly journals INFLAMMATION AS A CAUSE OF COUGH AND COMPLICATIONS: ROLE OF MODERN MUCOLYTICS

2021 ◽  
Vol 29 (2) ◽  
pp. 41-46
Author(s):  
M. M. Ostovskiy
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Controlled Trial ◽  
Lower Respiratory Tract Infections ◽  
Observation Study ◽  
Tract Infections ◽  
The Impact

A literature review regarding pharmacodynamics of mucolytic compound erdosteine (Ermucin by Edmond Pharma) has been presented in current publication. Mucolytic effect of this compound is based on the braking of disulfuric bonds, tiding the glycoproteine fibers, resulting in encreased elasticity and decreased viscosity of sputum. Erdosteine metabolites improve the effectiveness of muco-ciliary clearance of purulent and mucopurulent low respiratory tract secretions. Anti-inflammatory effect of erdosteine is mediated through the suppression of pro-inflammatory cytokines synthesis, such as IL-6 and IL-8, directly involved in neutrophilic immune response in bronchial tree and lung parenchyma. Additionally, erdostein acts as reactive oxygen species scavenger, preventing its local formation, decreasing 8-isoprostane level as a marker of lipid peroxidation. Erdostein, being used in 8-months courses, allows not only to manage COPD exacerbation, but also prevents it, improving the quality of life of the patients and modifying diseases outcomes. The impact of erdostein on the rate and duration of COPD exacerbations has been proved in randomized placebo-controlled trial RESTORE. The evidence from this study was used as a rationale for inclusion of erdosteine in 2019 GOLD Guidelines and national COPD guidelines. The results of the own limited open-label observation study of erdosteine efficacy in COVID-19 associated pneumonia, performed following the discharge of patients from Ivano-Frankivsk regional phthisiopulmonology center from 1 Jul 2020 till 25 Oct 2020 are presented in this article. The efficacy or erdosteine after one month therapy has been proved in study patients. On Day 30 of erdosteine therapy mMRC dyspnea score significantly decreased in 30.7 % of patients on the background of improved quality of life assessed by SGRQ questionnaire. The dosage and administration of erdosteine for management of cough in acute lower respiratory tract infections, COPD/chronic bronchitis exacerbations, exacerbation prevention and cough modification, recovery of physical activity in COVID-19 convalescents with secondary bacterial pneumonia, have been presented. Key words: lower respiratory tract infections, mucolytic therapy, erdosteine.

scholarly journals Evaluation of Clinical and Immunological Characteristics of Children with Common Variable Immunodeficiency

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Gülsüm Alkan ◽  
Sevgi Keles ◽  
İsmail Reisli
Keyword(s):  
Respiratory Tract ◽  
Common Variable Immunodeficiency ◽  
Respiratory Tract Infections ◽  
Disease Onset ◽  
Infection Prevalence ◽  
Diagnosis Delay ◽  
Upper Respiratory Tract ◽  
Onset Age ◽  
Tract Infections ◽  
Common Variable

Background. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder (PID) that typically presents with hypogammaglobulinemia and impaired antibody production. Objectives. This study aimed to promote the awareness of CVID, whose clinical spectrum is quite broad. Methods. The demographic, clinical, and laboratory characteristics of 12 children (seven males and five females) with CVID were analyzed retrospectively. The patients were diagnosed using the diagnostic criteria of the European Society for Primary Immunodeficiencies. Results. The median disease onset age was 7.2±4.1 years, and the mean diagnosis age was 11.6±3.7 years. The diagnosis delay was 4.3±2.6 years, and the parental consanguinity rate was 75%. Most patients presented with recurrent infections, including upper respiratory tract infections (n=8), lower respiratory tract infections (n=9), and gastroenteritis (n=5). In addition, growth retardation (n=9) and bronchiectasis (n=5) were common comorbidities. Two patients presented with autoimmune thrombocytopenia and anemia, and one patient exhibited lung empyema. All the patients had immunoglobulin G deficiencies. Conclusion. CVID is a heterogeneous disease, so the diagnosis is frequently delayed. In the CVID patients with pulmonary complications, relationships were seen with the diagnosis delay, symptom onset age, and lung infection prevalence. Overall, the early diagnosis and treatment of PIDs can preclude life-threatening complications.

Sign in / Sign up

Export Citation Format

Share Document